Document Detail


B4 androgen ablation: attacking the prostate cancer stem cell.
MedLine Citation:
PMID:  23348735     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is increasing evidence that prostate cancers in rodent models and in men contain a cellular subpopulation that displays stem cell properties. These prostate cancer stem cells (PCSCs) lack androgen receptor expression and are increased in castration-resistant disease. In this issue of the JCI, a study from Yoshioka et al. demonstrates that PCSCs are regulated by a pathway in which α6β4 integrin amplifies signaling through ErbB2 and c-Met receptors. Targeting this pathway provides a novel therapeutic strategy for hormone refractory prostate cancer.
Authors:
Max S Wicha
Related Documents :
23160385 - Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency doe...
25095855 - Metastatic tumors of the oral cavity.
18566225 - Stat3 inhibition in prostate and pancreatic cancer lines by stat3 binding sequence olig...
24997345 - Downregulation of ppp2r5e expression by mir-23a suppresses apoptosis to facilitate the ...
16246185 - Somatic mutations of mitochondrial dna in digestive tract cancers.
6841615 - Utility of mmpi indices of schizophrenia with adolescents.
Publication Detail:
Type:  Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-01-25
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  123     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-04-19     Completed Date:  2013-05-13     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  563-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Humans
Integrin beta4 / metabolism*
Male
Neoplastic Stem Cells / metabolism*,  pathology*
Prostatic Neoplasms / metabolism*,  pathology*
Grant Support
ID/Acronym/Agency:
CA101860/CA/NCI NIH HHS; CA66233/CA/NCI NIH HHS; P30CA46592/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Integrin beta4
Comments/Corrections
Comment On:
J Clin Invest. 2013 Feb 1;123(2):682-99   [PMID:  23348745 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?
Next Document:  Why stress is BAD for cancer patients.